Associations of metformin and sulfonylurea on vascular complications in early‐ and late‐onset type 2 diabetes: A cohort study

Sulfonylurea therapy was linked to increased cardiovascular risk, particularly in younger patients, while microvascular outcomes were comparable. These findings support metformin as the preferred first-line therapy for early-onset type 2 diabetes.